Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiaan Engelborghs

Showing results (211-220 of 359) with videos related to

Pageof 36
Sort By:
Neurobiology of Aging|November 1, 2011
Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohortsTim Van Langenhove, Julie van der Zee, Sebastiaan Engelborghs, et al.
Frontiers in Molecular Biosciences|April 17, 2020
A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau IsoformsJoke Verelst, Nick Geukens, Sabiha Eddarkaoui, et al.
Acta Neurologica Belgica|January 11, 2015
Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo surveyJean-Christophe Bier, Jurn Verschraegen, Rik Vandenberghe, et al.
Neurobiology of Aging|January 6, 2026
Rare ABCA7 mutations in Alzheimer's disease and cerebral amyloid angiopathy pathologyElisabeth Hendrickx Van de Craen, Liene Bossaerts, Anne Sieben, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 15, 2012
Guanosine triphosphate cyclohydrolase 1 promoter deletion causes dopa-responsive dystoniaJessie Theuns, David Crosiers, Luc Debaene, et al.
Journal of Alzheimer'S Disease : JAD|November 7, 2022
Improved Alzheimer's Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot StudyJorne Laton, Jeroen Van Schependom, Joery Goossens, et al.
Alzheimer'S Research & Therapy|August 24, 2018
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled studyMaarten Timmers, Johannes Rolf Streffer, Alberto Russu, et al.
Journal of Alzheimer'S Disease : JAD|May 26, 2019
Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia CouncilGaëtane Picard, Jean-Christophe Bier, Isabelle Capron, et al.
JAMA Neurology|January 7, 2015
Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob diseaseAline Dorey, Yannick Tholance, Alain Vighetto, et al.
Clinical Chemistry|March 11, 2018
Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison StudyEline A J Willemse, Ann De Vos, Elizabeth M Herries, et al.
Pageof 36

Showing results (211-220 of 359) with videos related to

Sort By:
Pageof 36
Neurobiology of Aging|November 1, 2011
Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohortsTim Van Langenhove, Julie van der Zee, Sebastiaan Engelborghs, et al.
Frontiers in Molecular Biosciences|April 17, 2020
A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau IsoformsJoke Verelst, Nick Geukens, Sabiha Eddarkaoui, et al.
Acta Neurologica Belgica|January 11, 2015
Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo surveyJean-Christophe Bier, Jurn Verschraegen, Rik Vandenberghe, et al.
Neurobiology of Aging|January 6, 2026
Rare ABCA7 mutations in Alzheimer's disease and cerebral amyloid angiopathy pathologyElisabeth Hendrickx Van de Craen, Liene Bossaerts, Anne Sieben, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 15, 2012
Guanosine triphosphate cyclohydrolase 1 promoter deletion causes dopa-responsive dystoniaJessie Theuns, David Crosiers, Luc Debaene, et al.
Journal of Alzheimer'S Disease : JAD|November 7, 2022
Improved Alzheimer's Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot StudyJorne Laton, Jeroen Van Schependom, Joery Goossens, et al.
Alzheimer'S Research & Therapy|August 24, 2018
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled studyMaarten Timmers, Johannes Rolf Streffer, Alberto Russu, et al.
Journal of Alzheimer'S Disease : JAD|May 26, 2019
Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia CouncilGaëtane Picard, Jean-Christophe Bier, Isabelle Capron, et al.
JAMA Neurology|January 7, 2015
Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob diseaseAline Dorey, Yannick Tholance, Alain Vighetto, et al.
Clinical Chemistry|March 11, 2018
Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison StudyEline A J Willemse, Ann De Vos, Elizabeth M Herries, et al.
Pageof 36